Publication | Open Access

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Dll3-targeted Antibody-drug ConjugateMedicineImmunologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerRovalpituzumab Tesirine